bibliographicCitation |
Lu Z, Yang S, Luo X, Shi Y, Lee J, Deva S, Liu T, Chao Y, Zhang Y, Huang R, Xu Y, Shen Z, Shen L. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. Gastric Cancer. 2022 Jul 02;25(5):943–55. doi: 10.1007/s10120-022-01308-7. |